Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading

2011 ◽  
Vol 21 (5) ◽  
pp. 372-379 ◽  
Author(s):  
A. Tuttolomondo ◽  
A. Pinto ◽  
D. Di Raimondo ◽  
S. Corrao ◽  
R. Di Sciacca ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hypertonic Saline ◽  
Natriuretic Peptide ◽  
Plasma Levels ◽  
Saline Solution ◽  
High Dose ◽  
Hypertonic Saline Solution ◽  
Saline Loading ◽  
Patients With Heart Failure ◽  
Cytokine Plasma

Small-Volume Hypertonic Saline Solution and High-Dosage Furosemide in the Treatment of Refractory Congestive Heart Failure

2000 ◽  
Vol 19 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Salvatore Paterna ◽  
Gaspare Parrinello ◽  
Pietra Amato ◽  
Ligia J. Dominguez ◽  
Antonio Pinto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Hypertonic Saline ◽  
Small Volume ◽  
Saline Solution ◽  
Hypertonic Saline Solution

The renal and cardiovascular effects of natriuretic peptides

2017 ◽  
Vol 41 (2) ◽  
pp. 179-185 ◽  
Author(s):  
Philip Ching Yat Wong ◽  
Jun Guo ◽  
Aidong Zhang
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Plasma Levels ◽  
Cardiovascular Effects ◽  
Target Cells ◽  
Natriuretic Peptide Receptor ◽  
Peptide Receptor ◽  
Endocrine Organs ◽  
Patients With Heart Failure

The landmark report by de Bold et al. in 1981 signified the heart as one of the endocrine organs involved in fluid and salt balance (de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. Life Sci 28: 89–94, 1981). Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are secreted from cardiomyocytes in response to cardiac stretch as in the case of heart failure, whereas C-type natriuretic peptide (CNP) is secreted from endothelial and renal cells in response to cytokines and endothelium-dependent agonists, such as acetylcholine. Binding ANP or BNP to natriuretic peptide receptor A induces cyclic guanylyl monophosphate as second messenger in the target cells to mediate the following: natriuresis; water diuresis; increasing glomerular filtration rate; decreasing systemic sympathetic activities; plasma volume; cardiac output and blood pressure; and curbing mitoses of heart fibroblasts and hypertrophy of cardiovascular muscle cells. ANP, BNP, and CNP are cleared from the bloodstream by natriuretic peptide receptor C and degraded by an ectoenzyme called neprilysin (NEP). The plasma levels of BNP are typically >100 pg/ml in patients with congestive heart failure. Sacubitril/valsartan is an angiotensin receptor NEP inhibitor that prevents the clinical progression of surviving patients with heart failure more effectively than enalapril, an angiotensin-converting enzyme inhibitor. A thorough understanding of the renal and cardiovascular effects of natriuretic peptides is of major importance for first-year medical students to gain insight into the significance of plasma levels of BNP in patients with heart failure.

Sign in / Sign up

Export Citation Format

Share Document